8-K
filed February 2, 2026, 6:59 PM ET
ticker PVCT
CIK 0000315545
other material
confidence high
sentiment neutral
materiality 0.35
Provectus extends automatic conversion date for Series D and D-1 preferred stock to Dec 2028
PROVECTUS BIOPHARMACEUTICALS, INC.
- Automatic conversion date for Series D and D-1 preferred stock extended from June 20, 2026 to December 31, 2028.
- Amendments apply to Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, both par value $0.001.
- Board of directors and a special committee of independent directors approved the amendments.
- No changes to conversion terms other than the extension of the conversion date.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001493152-26-004730
- form_type
- 8-K
- ticker
- PVCT
- cik
- 0000315545
- company_name
- PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at
- 2026-02-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:37.348755+00:00
- generated_at
- 2026-05-16T05:47:27.232954+00:00
- sec_items
- ["5.03", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.35
- calibrated_materiality_score
- 0.35
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001493152-26-004730
- json_url
- https://secwatch.observer/filing/0001493152-26-004730.json
- markdown_url
- https://secwatch.observer/filing/0001493152-26-004730.md
- text_url
- https://secwatch.observer/filing/0001493152-26-004730.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/0001493152-26-004730-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/form8-k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
IOT
Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026
Samsara Inc.
June 1, 2026, 4:07 PM ET
other_material
Items 3.03, 5.03, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time
Filing page
SEC filing
WORLDS INC
Worlds Inc. changes name to Gemaxel Inc., effective March 26, 2026
WORLDS INC
June 1, 2026, 2:59 PM ET
other_material
Items 5.03, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
On March 26, 2026 the Company amended ARTICLE FIRST of its Certificate of Incorporation and changed its name to Gemaxel Inc. from Worlds Inc.
Filing page
SEC filing
BTCS
BTCS reduces stockholder quorum requirement from majority to 33.3%
BTCS Inc.
June 1, 2026, 9:29 AM ET
other_material
Items 5.03, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
On May 29, 2026, the board of directors of BTCS Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) and adopted an amendment to the quorum requirement contained in Article II, Section 2.9 of the Bylaws (the “Amendment”) to provide that the holders of thirty-three and one third percent (33.3%) of the voting power of the Company entitled to vote at a meeting of stockholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business.
Filing page
SEC filing
MRNA
Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors
Moderna, Inc.
May 11, 2026, 7:59 PM ET
other_material
Items 5.03, 5.07, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.
Filing page
SEC filing
LKQ
LKQ stockholders approve 25% special meeting right; all director nominees elected
LKQ CORP
May 8, 2026, 7:59 PM ET
other_material
Items 5.03, 5.07, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
the Company’s stockholders, upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment (the “Charter Amendment”) to the Company’s Restated Certificate of Incorporation to provide stockholders holding a combined 25% or more of the Company’s common stock with the right to request a special meeting of stockholders.
Filing page
SEC filing
ENTG
Entegris shareholders eliminate supermajority voting; all directors elected
ENTEGRIS INC
May 8, 2026, 7:59 PM ET
other_material
Items 5.03, 5.07, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
On February 5, 2026, the Board approved the adoption of the Amended and Restated By-Laws of the Company to conform to the Second Amended and Restated Certificate of Incorporation. The Board’s approval of the Amended and Restated By-Laws was contingent upon the stockholders’ approval of the Second Amended and Restated Certificate of Incorporation. The Amended and Restated By-Laws became effective on May 7, 2026.
Filing page
SEC filing
MAN
ManpowerGroup declares $0.72 dividend; shareholders approve equity plan amendment and director removal without cause
ManpowerGroup Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 5.02, 5.03, 5.07, 8.01, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
the Board of Directors of the Company amended Section 3.3 of Article III of the Company’s Amended and Restated By-Laws (the “ By-Laws Amendment ”) to permit the removal of a director with or without cause by the affirmative vote of two-thirds of the outstanding shares of capital stock of the Company entitled to vote at a meeting of shareholders duly called for such purpose. The effective date of the By-Laws Amendment is May 8, 2026.
Filing page
SEC filing
CCTC
Latamed AI Corp. authorizes 5M shares of Series C Voting Preferred Stock (20 votes/share)
LataMed AI Corp.
May 8, 2026, 7:59 PM ET
other_material
Items 5.03, 9.01
same fact type: governance_change
same SEC item: 5.03, 9.01
same event type: other_material
similar materiality
This filing
On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.
Comparable filing
On May 6, 2026, the Board of Directors of LataMed AI Corp. (formerly Catalyst Crew Technologies Corp.) (the “Company”) approved the designation of a new series of preferred stock designated as the “Series C Voting Preferred Stock” and filed a Certificate of Designation with the Nevada Secretary of State establishing the rights, preferences, and limitations of such series.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.